TG Therapeutics Inc (NASDAQ:TGTX) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 15,260,495 shares, a decrease of 9.7% from the April 15th total of 16,903,739 shares. Currently, 19.7% of the shares of the company are sold short. Based on an average daily trading volume, of 1,600,456 shares, the days-to-cover ratio is currently 9.5 days.

A number of research analysts recently commented on TGTX shares. Jefferies Financial Group restated a “buy” rating and set a $8.00 price objective on shares of TG Therapeutics in a research note on Wednesday, February 6th. Zacks Investment Research downgraded TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 30th. BidaskClub upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of TG Therapeutics in a research note on Friday, April 12th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. TG Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.07.

Large investors have recently added to or reduced their stakes in the company. Forbes J M & Co. LLP bought a new position in shares of TG Therapeutics in the fourth quarter worth $44,000. LPL Financial LLC bought a new position in shares of TG Therapeutics in the fourth quarter worth $49,000. NumerixS Investment Technologies Inc bought a new position in shares of TG Therapeutics in the fourth quarter worth $50,000. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of TG Therapeutics by 46.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,927 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 2,200 shares in the last quarter. Finally, National Asset Management Inc. bought a new position in shares of TG Therapeutics in the fourth quarter worth $58,000. 56.39% of the stock is owned by institutional investors.

NASDAQ:TGTX opened at $7.20 on Friday. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $16.00. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 1.89.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.01. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. As a group, equities analysts predict that TG Therapeutics will post -1.61 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://theolympiareport.com/2019/05/25/short-interest-in-tg-therapeutics-inc-tgtx-declines-by-9-7.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Further Reading: Trading Options- What is a Strangle?

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.